EyePoint (EYPT) Other Non-Current Assets (2011 - 2026)
EyePoint (EYPT) posted Other Non-Current Assets of $9.3 million for Q1 2026, up 6102.67% sequentially from $150000.0 in Q4 2025, and up 6102.67% YoY from $150000.0 in Q1 2025.
EyePoint (EYPT) Other Non-Current Assets (2011 - 2026) Analysis & Trends
EyePoint has reported Other Non-Current Assets for 16 years, with the latest figure at $9.3 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 6102.67% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (up 6102.67% YoY) and the FY2025 annual result came in at $150000.0, down 97.43% from the prior year.
- Other Non-Current Assets grew to $9.3 million in Q1 2026 per EYPT's latest filing, from $150000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $9.3 million in Q1 2026 and troughed at $150000.0 in Q1 2022.
- A 5-year average of $1.8 million and a median of $150000.0 in 2022 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets plunged 97.43% in 2025, then soared 6102.67% in 2026.
- Over 5 years, Other Non-Current Assets stood at $150000.0 in 2022, then changed by 0.0% to $150000.0 in 2023, then soared by 3788.0% to $5.8 million in 2024, then slumped by 97.43% to $150000.0 in 2025, then jumped by 6102.67% to $9.3 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $9.3 million, $150000.0, and $5.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 9.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.37 Mn |
| Mar 31, 2026 | 9.30 Mn |
| Dec 31, 2025 | 150,000.00 |
| Sep 30, 2025 | 5.92 Mn |
| Jun 30, 2025 | 5.90 Mn |
| Mar 31, 2025 | 150,000.00 |
| Dec 31, 2024 | 5.83 Mn |
| Sep 30, 2024 | 150,000.00 |
| Jun 30, 2024 | 150,000.00 |
| Mar 31, 2024 | 150,000.00 |
| Sep 30, 2023 | 150,000.00 |
| Jun 30, 2023 | 150,000.00 |
| Mar 31, 2023 | 150,000.00 |
| Dec 31, 2022 | 150,000.00 |
| Sep 30, 2022 | 150,000.00 |
| Jun 30, 2022 | 150,000.00 |
| Mar 31, 2022 | 150,000.00 |
| Dec 31, 2021 | 150,000.00 |
| Sep 30, 2021 | 150,000.00 |
| Jun 30, 2021 | 150,000.00 |